Injured Palestinians pour into al-Aqsa Hospital in Deir al-Balah in the central Gaza Strip as exhausted medics try to help casualties from Israel's ground assault and bombardment.
In a bid to boost direct-to-consumer business for wineries, Vinpro and the Cape Winelands District Municipality have launched a new wine tourism research pilot programme. The programme aims to generate tourism.
LONDON (Reuters) -Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more treatments for cardiometabolic diseases. Novo, a Danish drugmaker whose share price rose 49% last year due to soaring demand for its weight-loss medicine Wegovy, said the partnerships with Omega Therapeutics and Cellarity Inc could lead to new treatments for people living with obesity and a type of liver disease known as MASH. The two separate research and development collaborations are the first announced under a framework deal that Novo signed in 2022 with Flagship Pioneering, a U.S. investment firm focused on life sciences.